Slow Pump Adoption And Regulatory Risks Will Eventually Support A Stronger Automated Insulin Future

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

16 Jan 26

Updated

10 Jul 26

Views

Not Invested

Shared on 10 Jul 26

Fair value Decreased 48%

BBNX: Regulatory Recalls And Legal Probe Will Drive A More Cautious Outlook

Beta Bionics faces fresh pressure after several regulatory recalls and a new legal probe that question how smoothly its insulin pump rollout is going. Some on Wall Street still point to progress on upcoming products, but the overall mood turns more cautious as expectations for growth and future profits come down.

2 views

Fair Value vs Share Price

US$13

vs US$14.5712.1% overvalued

32.5%

Revenue growth

11.8%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Beta Bionics

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with low risk.

Market capUS$600.6m

PB2.6x

Estimated Growth24.5%

Dividend YieldN/A

Full analysis

CEO & management

Sean Saint

CEO

3.8yrs

CEO Tenure

A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.